To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer
Histologically or cytologically confirmed high-risk resectable or borderline resectable pancreatic cancer;
18-75 years old (including 18 and 75 years old);
No BRCA1/2 or PALB2 mutation;
No previous pancreatic cancer resection, systemic therapy, or local radiation therapy;
With distant metastasis;
Have received blood transfusion treatment, blood products and hematopoietic factors, such as albumin and granulocyte colony-stimulating factor (G-CSF) within 14 days before enrollment;
Have received any surgery or invasive treatment or operation within 4 weeks before enrollment (except venous catheterization, puncture and drainage, etc.);
Allergic to the study drug or any of its adjuvants;